Public Perspectives of Using Social Media Data to Improve Adverse Drug Reaction Reporting

DOI:
10.1007/s40264-021-01042-6

Document Version
Final published version

Link to publication record in Manchester Research Explorer

Citation for published version (APA):
Bulcock, A., Hassan, L., Giles, S., Sanders, C., Nenadic, G., Campbell, S., & Dixon, W. (2021). Public Perspectives of Using Social Media Data to Improve Adverse Drug Reaction Reporting: A Mixed-Methods Study. Drug Safety, 44(5), 553-564. https://doi.org/10.1007/s40264-021-01042-6

Published in:
Drug Safety

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.
Public Perspectives of Using Social Media Data to Improve Adverse Drug Reaction Reporting: A Mixed-Methods Study

Alexander Bulcock1,2 · Lamiece Hassan3 · Sally Giles4 · Caroline Sanders4 · Goran Nenadic5 · Stephen Campbell4 · Will Dixon2

Abstract

Introduction Information on suspected adverse drug reactions (ADRs) voluntarily submitted by patients can be a valuable source of information for improving drug safety; however, public awareness of reporting mechanisms remains low. Whilst methods to automatically detect ADR mentions from social media posts using text mining techniques have been proposed to improve reporting rates, it is unclear how acceptable these would be to social media users.

Objective The objective of this study was to explore public opinion about using automated methods to detect and report mentions of ADRs on social media to enhance pharmacovigilance efforts.

Methods Users of the online health discussion forum HealthUnlocked participated in an online survey (N = 1359) about experiences with ADRs, knowledge of pharmacovigilance methods, and opinions about using automated data mining methods to detect and report ADRs. To further explore responses, five qualitative focus groups were conducted with 20 social media users with long-term health conditions.

Results Participant responses indicated a low awareness of pharmacovigilance methods and ADR reporting. They showed a strong willingness to share health-related social media data about ADRs with researchers and regulators, but were cautious about automated text mining methods of detecting and reporting ADRs.

Conclusions Social media users value public-facing pharmacovigilance schemes, even if they do not understand the current framework of pharmacovigilance within the UK. Ongoing engagement with users is essential to understand views, share knowledge and respect users’ privacy expectations to optimise future ADR reporting from online health communities.

1 Introduction

An adverse drug reaction (ADR) has been defined as “an appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product” [1]. Adverse drug reactions constitute a significant problem, causing up to 10% of all hospital admissions across Europe [2] and affecting the well-being and quality of life among many more.

In the UK, post-marketing drug safety is monitored and regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). One important source of drug safety information is the MHRA’s Yellow Card scheme [3], which collects information on suspected ADRs voluntarily reported by healthcare professionals and members of the public. Information about the scheme is provided via promotional materials, training and patient information leaflets. Similar systems exist in other countries [4].

Alexander Bulcock and Lamiece Hassan should be considered joint first authors.

Will Dixon
Will.Dixon@manchester.ac.uk

1 Health Education England, North West Deanery, UK
2 Division of Musculoskeletal and Dermatological Sciences, Centre for Epidemiology Versus Arthritis, The University of Manchester, Oxford Road, Manchester M13 9PL, UK
3 Division of Informatics, Imaging and Data Sciences, Centre for Health Informatics, The University of Manchester, Manchester, UK
4 Division of Population Health, Health Services Research and Primary Care, NIHR Greater Manchester Primary Care Patient Safety Translational Research Centre, The University of Manchester, Manchester, UK
5 School of Computer Science, The University of Manchester, Manchester, UK
The study aimed to: (a) determine experiences and levels of knowledge regarding medication safety and reporting among users of health-related social media platforms and (b) explore public views on using health-related social media data to increase reporting of ADRs for pharmacovigilance purposes via various means, including using automated methods that involve text mining.

2 Methods

A sequential explanatory mixed-methods design was used [19]. A quantitative online survey was used to assess the breadth of understanding, opinions, and experiences relevant to pharmacovigilance and ADRs among a large cross-section of online health discussion forum users. This was followed by a series of qualitative focus groups to explore the opinions and experiences expressed in the survey and address some of the more complex concepts, including text mining.

2.1 Online Survey

The survey was conducted in collaboration with HealthUnlocked, a large, internationally used, online social network for health. Reporting an average of 4.5 million visits per month, HealthUnlocked provides access to resources, support, and communities relevant to health conditions and well-being concerns [20]. Users can join over 700 condition-specific communities within the platform that focus on different conditions and patients. Communities vary in size; some of the larger communities have memberships in the tens of thousands [20], particularly those associated with common conditions or run by major health charities, for example, the National Rheumatoid Arthritis Society (N > 29,000), Asthma UK (N > 16,000) and the Anxiety and Depression Association of America (N > 50,000). The platform has also been used for scientific purposes, including conducting research into the dynamics among online communities for people with long-term conditions [21], describing the representativeness of users compared to wider patient populations [22] and involving patients in the drug development process [23].

A 20-item questionnaire was drafted based on conversations with HealthUnlocked staff, clinicians and the MHRA. We worked with the HealthUnlocked team and a local Manchester-based musculoskeletal patient involvement group to iteratively develop appropriate phrasing and format. The final version comprised four sections relevant to ADRs and medicines regulation: health and experience with medications; reporting side effects; the Yellow Card scheme; and demographics. Multiple choice, binary (yes/no) and free text items were included (see Appendix 1 of the Electronic Supplementary Material [ESM]).
The survey was uploaded to five communities on HealthUnlocked for people with the following health conditions: rheumatoid arthritis, fibromyalgia, respiratory conditions, thyroid conditions and/or mental health problems. We chose these to represent a variety of physical and mental health conditions, whilst targeting large communities with active membership. Users who logged into HealthUnlocked with a UK IP address were randomly selected via a pop-up request to participate in the survey. Potential participants were diverted to an information page where they were asked to consent to a series of statements to access the survey. The survey ran online from October to December 2017.

Survey responses were collected anonymously. As participants logged into HealthUnlocked to access the survey, we were able to place restrictions to ensure each user could only complete the survey once. Participation in the survey was voluntary and no incentives were offered. Participants could skip questions or exit at any time if they wished. We ran analyses using (a) all valid responses per question and (b) only for respondents who completed surveys in full; proportionally, responses did not materially differ so for ease of reporting and interpretation, only surveys that were completed in full (i.e. completers) were included in the final analysis. Demographic data were collected in the final section, thus characteristics of completers and non-completers could not be compared. Descriptive statistics (counts and proportions) and Chi squared tests ($p < 0.05$) were used to analyse responses. Separate results for men and women were reported in all tables and in the text, where percentages were under 20% or sex differences differed by more than 5 percentage points.

### 2.2 Focus Groups

We ran five qualitative focus groups across Greater Manchester during February 2019, after the survey results had been analysed. Following the analysis of survey results, we thought it unlikely that members of the public would have detailed knowledge about side-effect reporting and anticipated possible reluctance to participate in individual interviews with this narrow focus. In light of their many benefits [24], we instead chose to run focus groups and adopted a broader lens on health-related social media use to reduce pressure on individuals, gain contextual information and benefit from group interaction, for example, via comments, questions and even challenges between participants, with the intention of generating more detailed data about experience, attitudes and behaviours as well as understanding views on adverse-event reporting. We advertised on online health forums, social media platforms (Facebook and Twitter), and through local networks of condition-specific community groups and patient-facing recruitment organisations (e.g. http://www.researchforthefuture.org), many of whom had previously collaborated with the university. Eligibility was restricted to people who lived with at least one long-term condition of interest (the same range of conditions used as in the survey) and had used social media or online forums in relation to their health. Whilst our original intention was to select participants purposively based on key demographic and experience-based characteristics and to continue data collection until saturation was reached, ultimately convenience sampling was used to recruit people, based on interest, availability and resources.

Focus groups were conducted by two researchers experienced in using qualitative methods (LH, SG) with support from a third post-graduate student on two occasions where either one could not attend. Focus groups were held in various community and university venues. Three groups focused on a single health area (fibromyalgia, mental health and respiratory conditions). To accommodate participant schedules, the remaining two focus groups mixed participants from multiple conditions, namely: fibromyalgia and rheumatoid arthritis; and thyroid and respiratory conditions. Participants completed demographic questionnaires prior to discussions. A semi-structured topic guide was used to guide discussions (see Appendix 2 of the ESM), which followed up on topics addressed by the survey, including reasons for using social media to discuss health and medication; awareness of medication safety reporting mechanisms; and, after a short information session about the MHRA’s Yellow Card scheme, opinions about reusing social media for safety reporting purposes, including reporting ADRs to the MHRA. Researchers moderated the groups to ensure key questions were addressed, whilst allowing for a natural flow of conversation and balancing participation between members. Discussions were audio recorded, with consent from participants, and transcribed verbatim. Participants were paid £20 each for participating, plus travel expenses.

Data were analysed thematically [25], aided by qualitative software (NVivo). First, a basic coding framework was developed in advance, based on the expected range of responses; our previous reading and experience of conducting and analysing the survey data informed code development. Codes were intended to represent the semantic content of the data, rather than more ‘latent’ interpretations. Following data collection, two members of the research team coded transcripts, each taking the lead on coding half the transcripts and then cross-checking each other’s work to ensure reliability. Codes were added or discarded where needed and then grouped into themes (see Appendix 3 of the ESM). Accompanying theme names and descriptions were developed and refined iteratively, with constant reference to the original transcripts. We selected quotes that we considered representative of themes to ‘give a flavour’ of the raw data, illustrate the analytic narrative and add a layer of transparency to the analytical process. A patient

△ Adis
and public involvement group (N=4) with experience of long-term conditions and using social media advised on the study design (e.g. discussion topics) and advertisements for participants ahead of data collection. At a results-focused workshop, they commented on preliminary results, with the benefit of viewing anonymised data extracts, thus assisting our interpretation of the findings.

3 Results

The material presented in this paper focuses on data and findings most relevant to reusing social media data for improving ADR reporting. To support greater data integration or ‘mixing’ under our mixed-methods approach, a longstanding problem in mixed-methods research [19], we have assimilated the results of the quantitative survey and themes yielded by the qualitative focus group under pragmatically defined headings, rather than reporting them sequentially and separately. This strategy was intended to give equal weight to quantitative and qualitative components; however, the focus on overlapping material inevitably means that certain survey data and qualitative themes were deemed outside the scope of this paper (though may be reported elsewhere, in future).

The qualitative analysis yielded three main themes: knowledge about ADRs and reporting methods (theme 1), use of online forums (theme 2) and attitudes towards linking with the Yellow Card scheme (theme 3). Appendix 3 of the ESM provides an overview of how the three main qualitative themes derived were mapped against relevant survey questions.

3.1 Response Rate

Overall, 1791 surveys were started and 1359 (75.9%) of these were completed in full. Table 1 describes the characteristics of the 1359 completers and the 20 focus group participants.

The majority of survey respondents were women, and in particular white women (79%). Most (86%) respondents were aged 45 years and over and half (53%) were retired. Among women, over a third (38%) were visiting the thyroid community webpage, 5% were visiting mental health pages and the remainder were spread equally (18–20%) between the rheumatoid arthritis, fibromyalgia and respiratory groups. Among men, almost half of respondents (47%) were visiting respiratory group webpages, 5% were visiting mental health pages and the remainder were spread equally (14–17%) between the fibromyalgia, rheumatoid arthritis and thyroid groups. Participants reported a median of two (interquartile range: 1–3) health conditions from the checklist provided.

Commonly reported conditions among both women and men included depression (29%, N = 337; 30%, N = 58), hypertension (27%, N = 314; 32%, N = 61) and back pain (23%, N = 272; 28%, N = 53). Men who participated were more likely than women to report heart conditions (22% vs 7%; x² = 44.90, df = 1, p < 0.001), lung conditions (40% vs 19%; x² = 41.97, df = 1, p < 0.001) and diabetes mellitus (14.6% vs 5.17%; x² = 22.45, df = 1, p < 0.001). Although not listed as a pre-specified checklist option, women were more likely than men to spontaneously report thyroid problems using the free text box provided to note other conditions (26% vs 6%; x² = 36.10, df = 1, p < 0.001).

Focus group participants were mainly white and female, with a mean age of 46 years. Groups included a range of three to ten participants. Thyroid and fibromyalgia conditions were the most common main conditions reported among participants, followed by respiratory conditions, rheumatoid arthritis and mental health conditions. Focus group participants were generally engaged and enthusiastic, with the mean duration of groups lasting 108 min (range: 90–120 min).

3.2 Pre-Existing Beliefs, Awareness and Understanding of ADRs and Pharmacovigilance

Among survey respondents, prevention of similar side effects occurring among other patients was viewed as the most important reason for reporting side effects, garnering 88% agreement overall (Table 2). Over two-thirds of participants also agreed that reporting was important to understand the prevalence of side effects (82%) and to be recorded in patient records (75%).

Survey participants were asked to indicate their level of understanding about various aspects of monitoring medication safety using a five-point scale (Fig. 1). Overall, a third of people reported they had no knowledge about methods of monitoring medication safety. Knowledge levels decreased further when asked about specific aspects of medication safety, with over half indicating no knowledge of the MHRA or the Yellow Card scheme. Men and women indicated similar levels of knowledge, with one exception; women were more likely than men to report any level of knowledge with regard to how to complete Yellow Card forms (29% vs 21%; x² = 4.57, df = 1, p = 0.033).

Focus group participants were asked about their understanding of what constituted an ADR (theme 1). In two groups, such questions prompted comparisons of side effects due to medication, compared with symptoms of different conditions, drug-drug interactions and allergic reactions. For example:
“It’s very hard to know the difference, because I think the main things are if you’ve got skin rashes, and vomiting, that’s like an allergic response.” (P9, Respiratory, Theme 1)

Only two focus group participants had previously heard of the Yellow Card scheme specifically before we brought it up; both had respiratory conditions and had previously reported to the scheme themselves. Two others attending the mental health focus groups had a general level awareness that systems were in place to monitor medication safety, but could not describe the specifics. As one explained:

\[\begin{array}{l}
\text{Table 1 Characteristics of participants who (a) completed the online survey in full and (b) participated in focus groups.}
\end{array}\]

| Characteristic                          | Online survey, % (N) | Focus groups, N (%) |
|----------------------------------------|----------------------|---------------------|
|                                        | Women | Men | All | Women | Men | All |
| Gender                                 |       |     |     |       |     |     |
| Women                                  | 100 (1160) | 0 (0) | 85.4 (1160) | 75.0 (15) |
| Men                                    | 0 (0) | 100 (192) | 14.1 (192) | 25.0 (5) |
| Other                                  | 0 (0) | 100 (0) | 0.2 (2) | 0 (0) |
| Missing/prefer not to say              | 0 (0) | 100 (0) | 0.4 (5) | 0 (0) |
| Age group (years)                      |       |     |     |       |     |     |
| 16–18                                  | 0.1 (1) | 0.5 (1) | 0.2 (2) | 0 (0) |
| 18–24                                  | 1.29 (15) | 1.0 (2) | 1.3 (18) | 10.0 (2) |
| 25–34                                  | 4.6 (53) | 1.6 (3) | 4.2 (57) | 20.0 (4) |
| 35–44                                  | 8.7 (101) | 7.8 (15) | 8.5 (116) | 15.0 (3) |
| 45–54                                  | 26.0 (302) | 20.3 (39) | 25.2 (342) | 10.0 (2) |
| 55–64                                  | 35.8 (415) | 28.1 (54) | 34.8 (473) | 40.0 (8) |
| 65+                                    | 23.5 (273) | 40.6 (78) | 25.8 (351) | 5.0 (1) |
| Ethnicity                              |       |     |     |       |     |     |
| White                                  | 93.1 (1080) | 93.2 (179) | 92.9 (1262) | 90.0 (18) |
| Black                                  | 0.9 (10) | 0.5 (1) | 0.9 (12) | 0 (0) |
| Asian                                  | 1.3 (15) | 1.6 (3) | 1.3 (18) | 5.0 (1) |
| Mixed                                  | 1.0 (12) | 1.0 (2) | 1.0 (14) | 5.0 (1) |
| Other                                  | 0.3 (4) | 0.5 (1) | 0.4 (5) | 0 (0) |
| Missing/prefer not to say              | 3.4 (39) | 3.1 (6) | 3.5 (48) | 0 (0) |
| Employment status                      |       |     |     |       |     |     |
| Employed                               | 32.6 (378) | 22.9 (44) | 31.4 (427) | 30.0 (6) |
| Unemployed                             | 11.1 (129) | 9.9 (19) | 10.9 (148) | 35.0 (7) |
| Retired                                | 51.6 (599) | 65.1 (125) | 53.4 (726) | 20.0 (4) |
| Other                                  | 4.2 (49) | 2.1 (4) | 3.9 (53) | 15.0 (3) |
| Missing/prefer not to say              | 0.4 (5) | 0 (0) | 0.4 (5) | 0 (0) |
| HealthUnlocked community/main condition\(^a\) |       |     |     |       |     |     |
| Fibromyalgia                           | 19.8 (230) | 14.1 (27) | 18.9 (257) | 25.0 (5) |
| Mental health conditions               | 5.2 (60) | 5.7 (11) | 5.2 (71) | 15.0 (3) |
| Respiratory conditions                 | 18.2 (211) | 46.9 (90) | 22.3 (303) | 20.0 (4) |
| Rheumatoid arthritis                   | 18.4 (213) | 16.7 (32) | 18.0 (245) | 15.0 (3) |
| Thyroid conditions                     | 38.4 (446) | 16.7 (32) | 35.5 (483) | 25.0 (5) |
| Number of health conditions            |       |     |     |       |     |     |
| 1                                      | 35.7 (414) | 30.7 (59) | 35.0 (476) | 5.0 (1) |
| 2–3                                    | 44.1 (511) | 37.5 (72) | 43.0 (585) | 50.0 (10) |
| 4+                                     | 20.3 (235) | 31.8 (61) | 21.9 (298) | 45.0 (9) |
| Total                                  | 100 (1160) | 100 (192) | 100 (1359) | 100 (20) |

\(^a\)Survey participants self-reported their main condition. For survey participants, this indicates the relevant HealthUnlocked community participants were drawn from: Fibromyalgia Action UK, Mental Health Support, British Lung Foundation, National Rheumatoid Arthritis Society and Thyroid UK
I knew there was a way to report it and I knew that if I wanted to report something, I have to look on the leaflet with my medication, there’s a section there that says it.” (P1, Mental health, Theme 1)

3.3 Experience of Medication Side Effects and Reporting

The vast majority (89%, N = 1215) of survey participants reported having personally experienced a side effect from their medication. Experience of side effects ranged from 85% to 96% among different groups, with participants affiliated with the rheumatoid arthritis group indicating the highest rates. Over half (56%, N = 761) stopped taking their medication because of side effects and 9% (N = 128; 9% of women and 13% of men) were consequently admitted to hospital.

Survey participants were asked who they thought had a responsibility to report ADRs. Most frequently, respondents agreed that doctors or nurses had this responsibility (83%), although 72% agreed that patients who took medicines also shared this responsibility (Table 2). Among those who had experienced side effects, 74% (N = 1009) did report it to a general practitioner or hospital doctor; just 3% (n = 44; 4% of women and 1% of men) reported it to the MHRA.

Focus group participants reported that medication and side effects were popular topics of discussion online. Several participants described how online communities shared knowledge and experiences of side effects and strategies to overcome them. For example:

| Survey question                                                                 | Agreed, % (N)     |
|---------------------------------------------------------------------------------|-------------------|
| 1. Who do you think should be responsible for reporting drug side effects? Select all that apply. |                   |
| (a) Your doctor or nurse                                                       | 83.1 (964)        |
| (b) Pharmacists                                                                | 56.5 (655)        |
| (c) Drug companies                                                             | 45.1 (523)        |
| (d) Patients taking medications                                                | 72.0 (835)        |
| (e) Don’t know                                                                 | 4.1 (48)          |
| (f) Other                                                                      | 5.0 (58)          |
| 2. Which of these do you think are important reasons to report and monitor drug reactions? Select all that apply. |                   |
| (a) To find other people with similar reactions                                | 54.5 (632)        |
| (b) To learn how common such reactions are, or find out how many other people have had the same problem | 82.0 (951)        |
| (c) To help prevent similar side effects happening to other patients           | 88.2 (1023)       |
| (d) To help doctors make a diagnosis                                           | 46.9 (544)        |
| (e) To be recorded within my health record                                     | 75.5 (876)        |
| (f) Other                                                                      | 7.0 (81)          |
| 3. Would you be happy for the MHRA to use content posted on HealthUnlocked communities to help monitor side effects. Only de-personalised information would be used. | 94.1 (1092)       |
| 4. Would you be happy for researchers to use content posted on HealthUnlocked communities to help monitor side effects? Only de-personalised information would be used. | 94.7 (1098)       |
| 5. Which of the following would make it easier for you to complete Yellow Card submissions online? Select all that apply. |                   |
| (a) Link to the Yellow Card website from HealthUnlocked                        | 69.7 (809)        |
| (b) Suggestion to complete a Yellow Card if your post describes a side effect of medication via a promoted link to the Yellow Card website | 35.6 (413)        |
| (c) Suggestion to complete a Yellow Card if your post describes a side effect of medication via a pop-up Yellow Card form in HealthUnlocked | 32.4 (376)        |
| (d) Suggestion to complete a Yellow Card if your post describes a side effect of medication via a pop-up Yellow Card form in HealthUnlocked, with the form partially filled in automatically from details of your post | 35.8 (415)        |
| (e) Other                                                                      | 4.1 (47)          |
“Because there’s no one size fits all treatment for it, everybody with fibro is given a different combination of medication and treatment … we have people coming on saying I’ve been taking such a tablet, I’m really ill. And we give the advice, well, you should also be taking this other tablet to combat it. And again, we’re giving more advice out than some doctors.” (P2, Fibromyalgia, Theme 2)

Two participants with respiratory conditions had personal experience of reporting to the Yellow Card scheme; one explained her reasoning:

It’s maybe to help the drug companies see how many people are reporting side effects. I don’t know if that’s correct or not. But that’s how I see it. So, I always think well, it’s beneficial to do that every time. And particularly if it’s a severe side effect. I don’t think I’ve done it if it’s been mild side effects. But if I’ve noticed things that are maybe not on the list as well, on the packet, I’ve done it then. (P9, Respiratory, Theme 1)

3.4 Engaging Users of Health-Related Social Media Platforms

Well over 90% of survey participants said they would be happy for researchers or the MHRA to use content posted on HealthUnlocked to help monitor side effects (Table 2). Focus group participants gave a range of reasons for being supportive in principle of encouraging users of online forums to report side effects to the Yellow Card scheme (Table 3). One strong reason for support that was independently raised at three focus groups was the potential to raise awareness about the Yellow Card scheme in general among a large and distinct population, likely to be engaged in health issues (Table 4).

“I do [think it’s a good idea], yeah, because there’s people are already saying they’ve got side effects, and plainly the two do need to be linked because those people may not know about the Yellow Card, like we didn’t.” (P4, Thyroid/respiratory, Theme 3)

“I suppose it would create awareness for the younger generation that might not know about it.” (P3, Respiratory, Theme 3)

Nonetheless, their support was not unconditional and several reasons to be cautious were outlined (Table 3). Reservations about preserving privacy and sharing personal data online with a hitherto unfamiliar organisation (i.e. the MHRA) were raised in four focus groups. Concerns about the consequences of excluding the experiences of people without digital skills or access to internet forums was also common. A few also questioned the intentions and integrity of parties monitoring side effects and discussed the implications of surveillance.

“They’re asking for email, phone number, home address, full name, and then they’re asking what medication you’re taking. I don’t think they need to know all that information.” (P5, Fibromyalgia, Theme 3)

“I suppose the information could be massaged – for want of a better word – to try and sort of decrease
the importance of the impact of the side effects.” (P6, Thyroid/respiratory, Theme 3)

### 3.5 Attitudes Towards Automated Reporting Methods

Survey respondents were presented with four pre-specified, non-mutually exclusive proposals for making it easier for HealthUnlocked users to report side effects to the Yellow Card scheme (Table 2). Two-thirds (70.2%) of survey respondents agreed that a link to the Yellow Card scheme from the HealthUnlocked site would make it easier for them to report side effects. Respondents were also asked whether specifically targeting posts that discussed side effects would be beneficial, whether via promoted links, pop-ups (a small window that appears on screen) or pop-ups including partially completed forms with details automatically extracted from the posts. These three methods, henceforth referred to as ‘automated methods’, proved less popular among respondents, with roughly a third agreeing to each of them individually (Table 2), and 62% (N = 844) agreeing to any of these automated methods.

There were no substantial demographic differences between participants who preferred simple links, automated methods, both types of methods or none of them (Table 4). A Venn diagram was generated (see Appendix 5 of the ESM) to display the overlap of responses among participants who agreed that any or both methods might be useful. This shows that while a link was the most commonly selected single option, preferences did vary among participants with no particular combination of choices garnering a majority.

The opinions of focus group participants were also divided regarding which methods might work best. In four focus groups, participants discussed the benefits of some degree of automation. This was generally deemed acceptable and consistent with tailored marketing approaches elsewhere online, a sign of “moving with the times”.

“So from an IT perspective, yeah, it’s a brilliant idea. Because if you use cookies to log what people are saying, you could very easily pop up an advert just like what Facebook does.” (P8, Fibromyalgia/Rheumatoid arthritis, Theme 3)
A few people particularly welcomed the ease of a partially completed form, providing it was editable and could be checked for accuracy. Common reasons for rejecting this option were security concerns and mistrust of unknown organisations (including the MHRA) and/or pop-ups.

“I think you’d have to be sure that it wasn’t some rogue pop-up, because that’s the main thing. And I think people would be wary of it.” (P9, Respiratory, Theme 3)

“But they’re just going to see it as a scam. Somebody trying to get your details off you.” (P8, Fibromyalgia/Rheumatoid arthritis, Theme 3)

Whilst participants attending the mental health-themed focus group did not overtly disagree with the principal of engaging social media users, they were the most critical of automated methods. In particular, there was doubt about the ability of algorithms to adequately deal with subtleties, bias and context.

“I think it would be quite difficult because you can just film it and put it on your story for 24 h and delete it if you want to ... that’s going to take a very complex algorithm to realise all the different accents, all the different ways of saying depression or antidepressant ... the context.” (P7, Mental health, Theme 3)

“I’m a bit sceptical of these types of things online ... I think technology has limited how intelligent it can get, whereas a person, if you’re describing symptoms to a person, side-effects, whatever, I think people, and doctors especially, I think they have some sort of a sensitivity.” (P10, Mental health, Theme 3)

4 Discussion

4.1 Summary of Findings

Our findings indicate low levels of knowledge among users of health-related social media platforms about pharmacovigilance measures in general and the Yellow Card scheme specifically. This was despite 89% of survey respondents

| Characteristics of survey respondents, by type of agreement with proposed reporting methods to improve reporting to the Yellow Card scheme |
|---|
| | (a) Links | (b) Automated methods | (c) Links and automated methods | (d) None of these |
| **Sex** | | | | |
| Women | 34.7 (402) | 27.6 (320) | 35.1 (407) | 2.7 (31) |
| Men | 36.5 (70) | 21.9 (42) | 37.0 (71) | 4.7 (9) |
| **Age group (years)** | | | | |
| Under 55 | 32.3 (172) | 27.6 (147) | 37.9 (202) | 2.3 (12) |
| 55 and over | 36.7 (303) | 26.4 (218) | 33.5 (277) | 3.4 (28) |
| **Ethnicity** | | | | |
| White | 34.5 (435) | 26.9 (340) | 35.7 (450) | 2.9 (37) |
| BAME | 32.7 (16) | 22.4 (11) | 40.8 (20) | 4.1 (2) |
| **Employment status** | | | | |
| Employed | 34.7 (148) | 26.2 (112) | 36.1 (154) | 3.0 (13) |
| Not employed | 35.1 (327) | 27.1 (253) | 34.9 (325) | 2.9 (27) |
| **HealthUnlocked community** | | | | |
| Fibromyalgia | 33.5 (86) | 28.0 (72) | 35.0 (90) | 3.5 (9) |
| Mental health conditions | 31.0 (22) | 22.5 (16) | 40.8 (29) | 5.6 (4) |
| Respiratory conditions | 39.6 (120) | 24.8 (75) | 33.0 (100) | 2.6 (8) |
| Rheumatoid arthritis | 33.9 (83) | 28.6 (70) | 35.9 (88) | 1.6 (4) |
| Thyroid conditions | 34.0 (164) | 27.3 (132) | 35.6 (172) | 3.1 (15) |
| **Number of health conditions** | | | | |
| 1 | 35.5 (169) | 27.3 (130) | 33.8 (161) | 3.4 (16) |
| 2–3 | 34.7 (203) | 27.2 (159) | 35.9 (210) | 2.2 (13) |
| 4+ | 34.6 (103) | 25.5 (76) | 36.2 (108) | 3.7 (11) |
| All | 35.0 (475) | 26.9 (365) | 35.2 (479) | 2.9 (40) |

BAME Black, Asian and Minority Ethnicities
having previously experienced side effects because of taking prescribed medicines.

Participant responses from both the survey and the focus groups indicated a strong willingness to engage with the monitoring of side effects and to share health-related social media data about ADRs with researchers and regulators. HealthUnlocked users strongly supported the option of enabling users to submit ADR reports from within the HealthUnlocked platform using an online form, with two-thirds indicating that a link to the Yellow Card website from HealthUnlocked would be helpful. However, they were less united in their support when it came to proposing automated methods of surveillance to monitor posts in real time and actively suggest that users report suspected ADRs. None of the automated methods proposed, including promoted links, pop-ups or partially completed forms, gained majority support, even among demographic subgroups. Follow-up focus groups revealed a range of perceived risks and disadvantages associated with introducing measures to increase reporting among social media users that could explain this caution, some of which (but not all) were specific to automated methods.

4.2 Comparison with Existing Literature

Our results are consistent with previous studies that have shown that public awareness and uptake of the Yellow Card scheme is low generally [5–7]. Yet, both survey and focus group participants mostly agreed that patients had a significant role to play in reporting ADRs and, when made aware about the Yellow Card scheme, responded positively. This indicates that patients view public facing pharmacovigilance schemes as important, even if they do not understand the current framework of pharmacovigilance within the UK.

Our results suggested that social media users were, in principle, generally happy for data they generate to be shared with the MHRA and researchers for pharmacovigilance purposes. However, they differed in opinion about what methods they would prefer and which would work best. A previous qualitative study by Golder et al. also found that the majority of participants were broadly supportive of the use of social media to monitor ADRs but lacked awareness around the MHRA and Yellow Card scheme [26]. This was confirmed in our study; the focus groups further revealed that this lack of familiarity fed into a specific reluctance to respond to pop-up invitations on security grounds. For these reasons, our findings support continuing work towards public engagement efforts, examples of which can be found not only in the UK but worldwide, such as the ‘take and tell’ campaign [27], to normalise side-effect reporting and increase that transparency of pharmacovigilance efforts.

Golder et al. also reported some concerns about privacy and the need for autonomy over data uses [26]. Insights from our study also showed that participants worried about sharing personal information and wanted control over what was being shared, not just to protect privacy but also to assess accuracy. Some focus group participants, particularly those attending the mental health session, raised doubts about relying on potentially biased social media reports and the ability of automated methods to distinguish ‘true’ ADRs. Though this was not proposed to focus group participants, some of their more minor concerns regarding automatic detection of ADRs (e.g. detecting misspellings, duplicate posts or decoding acronyms) could perhaps be satisfactorily addressed by modern text analytic techniques [14, 15, 28]. Providing patients with the opportunity to formally trial the performance and usability of proposed systems, including viewing and amending information automatically extracted from sample social media posts, could possibly be a useful avenue for future development to gather even more informed views. Notably, a recent citizens’ jury study [29] showed that patients were supportive of using free text data in patient records, once more familiar with text mining methodologies. Even so, concerns about bias and accuracy cannot be ignored and may indeed be shared by experts: currently, the performance of ADR detection algorithms is complex [14] and the quality of different sources of social media data for research and pharmacovigilance purposes has been questioned [10, 28, 30, 31].

4.3 Strengths and Limitations

This study benefited from surveying a large sample of users, even in comparison to other surveys using HealthUnlocked [32, 33], of a leading online health social networking platform. The sequential mixed-methods design took time to complete, but allowed both breadth and depth of analysis, enhancing our ability to probe uncertainties and develop a more accurate picture of user perspectives. Compared to the general population, white middle-aged women were over-represented among both our survey and focus group participants. Though representative of HealthUnlocked members (our target audience), a recent annual user survey reported a mostly female (72%) and older membership, with 60% of users surveyed aged 60 years and over [34], we cannot comment on the generalisability of findings among patients who use other social media platforms. Furthermore, selection bias may have affected our study as people who had heard of the Yellow Card scheme may have been more likely to participate. An inadequate response rate to study advertisements meant we relied on convenience sampling to maximise recruitment to focus groups, accepting anyone who met the eligibility criteria and was available.
Whilst those who did participate engaged fully and provided detailed responses, qualitative data collection ceased before true saturation was reached, meaning that we cannot be certain that we did not miss important perspectives. These are limitations of the study. Although we relied on conducting face-to-face focus groups, on reflection, online methods may have encouraged greater diversity and participation.

Because of the complexity of the automated ADR detection techniques involved, it is possible that participants did not fully understand the methods and options presented to them, particularly in the survey where space was limited. By providing information about the Yellow Card scheme and the details of the proposals for improving ADR reporting in focus groups, we may have addressed gaps in knowledge to allow participants to give more informed views; however neutral we strived to be, this may have introduced bias. Future studies on such topics may wish to consider deliberative designs [35], which formally allow for both information provision and discussion, with procedures to reduce bias. Resources and our preference for maximising participation influenced our choice of study design on this occasion.

5 Conclusions

Public participation in formal ADR reporting schemes is low, yet many people with long-term health conditions are willing to discuss their health, including medication side effects, with their peers on social media platforms. The use of social media as a source of insights of value for pharmacovigilance purposes is still in an early stage of development. Studies show it is technically feasible to extract data about ADRs from free text discussions on social media platforms using computer algorithms. Yet, there are unanswered ethical questions about the relative benefits and risks. Our study shows that HealthUnlocked users were supportive in principle of promoting awareness of ADR reporting and sharing social media data with both regulatory bodies and researchers for pharmacovigilance purposes. However, they were cautious about accepting the use of automated methods using text mining techniques. In tandem with technical developments, ongoing engagement with users is also essential to understand views, share knowledge and respect users’ privacy expectations to optimise future ADR reporting from patients within these settings.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s40264-021-01042-6.

Acknowledgements We gratefully acknowledge input from HealthUnlocked, our patient involvement groups and study participants. We are also grateful to Phil Tregunno at the MHRA for discussions about this work.

Declarations

Funding The project was supported by the Centre for Epidemiology Versus Arthritis (Ref: 21755). Lamiece Hassan was supported by a grant from the Medical Research Council (Ref: MR/S004025/1).

Conflicts of interest/competing interests Will Dixon has received consultancy fees from Bayer, Abbvie and Google unrelated to this work. Alexander Bulcock, Lamiece Hassan, Sally Giles, Caroline Sanders, Goran Nenadic and Stephen Campbell have no conflicts of interest that are directly relevant to the content of this article.

Ethics approval Ethical approval was granted by University of Manchester Research Ethics Committee (Ref: 2017-1713-3835).

Consent to participate Informed consent was obtained from all individual participants included in the study.

Consent for publication Not applicable.

Availability of data and material Not applicable.

Code availability Not applicable.

Authors’ contributions WD, CS, GN and SC conceived the work. AB collected, analysed and interpreted the survey data. LH analysed and interpreted the survey data. LH and SG collected, analysed and interpreted the qualitative data. All authors contributed to the design of the work. LH and AB drafted the paper. All authors contributed towards critical revisions and approved the final version for publication.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.
2. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl. 1):S73–7.
3. MHRA. Yellow Card. https://yellowcard.mhra.gov.uk/. Accessed 9 Mar 2020.
4. Getz KA, Stergiopoulos S, Kaitin KI. Evaluating the completeness and accuracy of MedWatch data. Am J Ther. 2014;21(6):442–6.
5. McIlernon DJ, Bond CM, Lee AJ, Watson MC, Hannaford PC, Fortnum H, et al. Patient views and experiences of making adverse drug reaction reports to the Yellow Card scheme in the UK. Pharmacoepidemiol Drug Saf. 2011;20(5):523–31.

△ Adis
6. O’Donovan B, Rodgers RM, Cox AR, Kraska J. Making medicines safer: analysis of patient reports to the UK’s Yellow Card scheme. Expert Opin Drug Saf. 2019;18(12):1237–43.
7. Fortnum H, Lee AJ, Rupnik B, Avery A; Yellow Card Study Col- laboration. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. J Clin Pharm Ther. 2012;37(2):161–5.
8. NHS. Yellow Card. 2020. https://www.nhs.uk/apps-library/yel low-card/. Accessed 27 Nov 2020.
9. Freifeld CC, Brownstein JS, Menone CM, Bao W, Filice R, Kass-Hout T, et al. Digital drug safety surveillance: monitoring phar-maceutical products in Twitter. Drug Saf. 2014;37(5):343–50.
10. Kim Y, Huang J, Emery S. Garbage in, garbage out: data collec-
tion, quality assessment and reporting standards for social media data use in health research, infodemiology and digital disease detection. J Med Internet Res. 2016;18(2):e41.
11. Fox S, Duggan M. Health Online 2013. Washington, DC: Pew Research Centre; 2013. https://www.pewresearch.org/inter
dnet/2013/01/15/health-online-2013/. Accessed 22 Jan 2021.
12. Nikfarjam A, Sarker A, O’Connor K, Ginn R, Gonzalez G. Phar-
macovigilance from social media: mining adverse drug reaction men-
tions using sequence labeling with word embedding cluster features. J Am Med Inform Assoc. 2015;22(3):671–81.
13. Ginn R, Pimpalkhute P, Nikfarjam A, Patki A, Oconnor K, Sarker A, et al. Mining Twitter for adverse drug reaction mentions: a corpus and classification benchmark. In: Proc fourth work build eval resour heal biomed text process. 2014;(1). http://www.nactem.ac.uk/biotxtm2014/papers/Ginne tal.pdf
14. Sarker A, Ginn R, Nikfarjam A, O’Connor K, Smith K, Jayaram-
man S, et al. Utilizing social media data for pharmacovigilation: a review. J Biomed Inform. 2015;54:202–12.
15. Sarker A, Belousov M, Friedrichs J, Hakala K, Kiritchenko S, Mehryary F, et al. Data and systems for medication-related text class-
ification and concept normalization from Twitter: insights from the Social Media Mining for Health (SMM4H)-2017 shared task. J Am Med Inform Assoc. 2018;25(10):1274–83.
16. Goldner S, Ahmed S, Norman G, Booth A. Attitudes toward the ethics of research using social media: a systematic review. J Med Internet Res. 2017;19(6):e195.
17. Taylor J, Pagliari C. Mining social media data: how are research sponsors and researchers addressing the ethical challenges? Res Ethics. 2018;14(2):1–39. https://doi.org/10.1177/1747016117738559.
18. Brady E, Segar J, Sanders C. “I always vet things”: navigating privacy and the presentation of self on health discussion boards among individuals with long-term conditions. J Med Internet Res. 2016;18(10):e274.
19. Ivankova NV, Creswell JW, Stick SL. Using mixed-methods sequential explanatory design: from theory to practice. Field Methods. 2006;18(3):3–20.
20. HealthUnlocked. https://healthunlocked.com/. Accessed 13 May 2020.
21. Joglekar S, Sastry N, Coulson NS, Taylor SJC, Patel A, Duschinskiy R, et al. How online communities of people with long-term conditions function and evolve: network analysis of the structure and dynamics of the asthma UK and British Lung Foundation online communities. J Med Internet Res. 2018;20(7):e238.
22. Costello R, Jacklin C, Jameson Evans M, McBeth J, Dixon WG. Representativeness of a digitally engaged population and a patient organisation population with rheumatoid arthritis and their willingness to participate in research: a cross-sectional study. RMD Open. 2018;4(1):e000664.
23. Anand A, Brandwood HJ, Jameson Evans M. Improving patient involvement in the drug development process: case study of potential applications from an online peer support network. Clin Ther. 2017;39(11):2181–8.
24. Kitzinger J. Qualitative research: introducing focus groups. BMJ. 1995;311(7000):299.
25. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.
26. Goldner S, Scantlebury A, Christmas H. Understanding public attitudes toward researchers using social media for detecting and monitoring adverse events data: multi methods study. J Med Internet Res. 2019;21(8):e7081.
27. Uppsala Monitoring Centre. Take and tell. http://www.takeandtell Long/. Accessed 1 Dec 2020.
28. van Stekenborg J, Ellenius J, Maskell S, Bergvall T, Caster O, Dasgupta N, et al. Recommendations for the use of social media in pharmacovigilance: lessons from IMI WEB-RADR. Drug Saf. 2019;42(12):1393–407. https://doi.org/10.1007/s40264-019-00858-7.
29. Ford E, Oswald M, Hassan L, Bozenthko K, Nenadic G, Cassell J. Should free text data in electronic medical records be shared for research? A citizens’ jury study in the United Kingdom. J Med Ethics. 2020;46(6):367–77.
30. Smith H, Bulbul A, Jones CJ. Can online discussion sites generate quality data for research purposes? Front Public Health. 2017;5:156.
31. Vivekanantham A, Belousov M, Hassan L, Nenadic G, Dixon WG. Patient discussions of glucocorticoid-related side effects within an online health community forum. Ann Rheum Dis. 2020;79(8):1121–2.
32. Costello R, Patel R, Humphreys J, McBeth J, Dixon WG. Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community. BMJ Open. 2017;7(4):e014603.
33. Simacek K, Raja P, Chiauzzi E, Eek D, Halling K. What do ovarian cancer patients expect from treatment? Perspectives from an online patient community. Cancer Nurs. 2017;40(5):E17–27.
34. HealthUnlocked. The patient engagement and insights report: insights from our 2019 Annual User Survey. 2019. https://about.healthunlocked.com/patient-engagement-insights-report. Accessed 22 Jan 2021.
35. Rothwell E, Anderson R, Botkin JR. Deliberative discussion focus groups. Qual Health Res. 2016;26(6):734–40. https://doi. org/10.1177/1049732315591150.